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Abstract
Introduction: Research on co-enrollment practices and their impact are limited in the ICU setting. The objectives
of this study were: 1) to describe patterns and predictors of co-enrollment of patients in a thromboprophylaxis trial,
and 2) to examine the consequences of co-enrollment on clinical and trial outcomes.
Methods: In an observational analysis of an international thromboprophylaxis trial in 67 ICUs, we examined the co-
enrollment of critically ill medical-surgical patients into more than one study, and examined the clinical and trial
outcomes among co-enrolled and non-co-enrolled patients.
Results: Among 3,746 patients enrolled in PROTECT (Prophylaxis for ThromboEmbolism in Critical Care Trial), 713
(19.0%) were co-enrolled in at least one other study (53.6% in a randomized trial, 37.0% in an observational study
and 9.4% in both). Six factors independently associated with co-enrollment (all P < 0.001) were illness severity
(odds ratio (OR) 1.35, 95% confidence interval (CI) 1.19 to 1.53 for each 10-point Acute Physiology and Chronic
Health Evaluation (APACHE) II score increase), substitute decision-makers providing consent, rather than patients
(OR 3.31, 2.03 to 5.41), experience of persons inviting consent (OR 2.67, 1.74 to 4.11 for persons with > 10 years’
experience compared to persons with none), center size (all ORs > 10 for ICUs with > 15 beds), affiliation with trials
groups (OR 5.59, 3.49 to 8.95), and main trial rather than pilot phase (all ORs > 8 for recruitment year beyond the
pilot). Co-enrollment did not influence clinical or trial outcomes or risk of adverse events.
Conclusions: Co-enrollment was strongly associated with features of the patients, research personnel, setting and
study. Co-enrollment had no impact on trial results, and appeared safe, acceptable and feasible. Transparent
reporting, scholarly discourse, ethical analysis and further research are needed on the complex topic of co-
enrollment during critical illness.
Introduction
Clinical trials are essential to improve care and reduce
morbidity and mortality in the intensive care unit (ICU).
Some critically ill patients are eligible for more than one
study. Restricting enrollment to only one study when
patients are eligible for more than one is a potentially
modifiable barrier to recruitment [1]. Testing two inter-
ventions concurrently can be achieved with a factorial
design as used successfully by the Acute Respiratory Dis-
tress Syndrome Network. In other circumstances, when
trials are initiated by different investigators at different
times, with different inclusion and exclusion criteria,
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co-enrollment can facilitate either sequential or simulta-
neous recruitment (Figure 1).
Co-enrollment in multiple trials, often driven by
patient demand, occurs in persons with human immuno-
deficiency virus (HIV) [2], and was documented among
23% of persons with HIV in six ongoing studies [3]. In
this population, co-enrollment is actively encouraged by
some research programs [3] but not others [2]. In pre-
hospital resuscitation trials, co-enrollment occurs either
in series or in parallel [4]. Half of the members of two
critical care research consortia reported co-enrollment of
a patient in more than one study in the last year [5]. In a
parental survey, 74% endorsed enrollment of their pre-
mature babies in 2 or more studies, 50% would consent
to 3 or more studies, and 10% were willing to join more
than 10 studies [6].
Some Institutional Review Boards restrict the practice
of co-enrollment, while concerned about patient safety,
decisional burden or scientific integrity. Given the dearth
of evidence on these issues, trialists have called for con-
sideration of co-enrollment on a case-by-case basis, and
reporting on its impact [7]. The primary objective of this
study was to document the patterns and predictors of
patient co-enrollment in an international heparin throm-
boprophylaxis trial. The secondary objective was to
examine the consequences of co-enrollment on clinical
and trial outcomes.
Materials and methods
PROTECT (Prophylaxis for ThromboEmbolism in Criti-
cal Care Trial) (clinicaltrials.gov NCT00182143) was a
randomized, blinded clinical trial comparing unfractio-
nated heparin to dalteparin for thromboprophylaxis [8].
Patients considered eligible were ≥ 18 years old, weighed
> 45 kilograms, and were expected to remain in ICU
> 72 hours. Exclusion criteria were admission diagnosis
of trauma, neurosurgery or orthopedic surgery, need for
therapeutic anticoagulation, receipt of > 72 hours of
heparin, contraindication to heparin, blood or pork pro-
ducts, pregnancy, life support limitation, and prior
enrollment in this or a related trial. The primary out-
come was proximal leg deep vein thrombosis (DVT).
Other outcomes were pulmonary embolism, venous
thromboembolism, bleeding, heparin-induced thrombo-
cytopenia, duration of mechanical ventilation, ICU and
hospital stay, and ICU and hospital mortality. PRO-
TECT was conducted over four years from May 2006 to
June 2010 in 67 ICUs in Canada, the United States, the
United Kingdom, Australia, Brazil and Saudi Arabia, as
published previously [9].
Ethical approval was obtained from each participating
Institutional Research Board (listed at the end of the
manuscript under PROTECT Collaborators). In-person
informed consent was required prior to randomization.
Deferred consent was not permitted. For substitute deci-
sion-makers not in hospital, initial telephone consent,
followed by in-person consent when possible, was
approved in 16 of the 67 (23.9%) centers.
Beginning and throughout the trial, the PROTECT
Steering Committee reviewed each multicenter protocol
to decide whether co-enrollment was admissible, using
Canadian Critical Care Trials Group guidelines [10].
These guidelines outline important scientific (for exam-
ple, interacting interventions), psychosocial (for example,
family stress) and logistic (for example, research coordi-
nator workload) factors to consider. The general
approach to co-enrollment was that all reasonable
efforts should be made to minimize the exclusion of
patients co-enrolled in another trial if they would likely
represent those patients to whom trial results would
possibly be applied in practice, as long as biologic inter-
action of the interventions being tested in the two trials
seemed highly implausible. Dialogue between the princi-
pal investigator and steering committees of each multi-
center study determined whether co-enrollment would
impact the scientific integrity of either study. When
relevant, this was reasoned at the Canadian Critical Care
Trials Group or the Australian and New Zealand Inten-
sive Care Society Clinical Trials Group meetings for
refutation or ratification. If co-enrollment was endorsed,
each participating center handled the relevant study
governed by formal or informal co-enrollment policies
of their ICU or hospital Institutional Review Board.
Local policies could deny co-enrollment approved cen-
trally. Local, single-center study co-enrollment could
also be approved after agreement with the PROTECT

















Figure 1 Factorial and co-enrollment designs. In this figure, we
present a schematic for a factorial design randomized trial,
sequential co-enrollment in two randomized trials and simultaneous
co-enrollment in two randomized trials.
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Decisions were revisited if emerging evidence required
reconsideration (Figure 2). All other studies into which
patients were enrolled before, concurrent with, or subse-
quent to PROTECT were documented on case report
forms.
One example was co-enrollment into the Age of Blood
Evaluation Study (ABLE, ISRCTN44878718). ABLE is a
randomized trial evaluating mortality following transfusion
of red blood cells stored up to one week versus stored up
to 42 days [11]. Both PROTECT and ABLE investigators
initially endorsed co-enrollment. Months later, an observa-
tional trauma study suggested that among a subgroup of
patients transfused with more than five units, when
patients received blood stored less than, versus more than,
28 days, DVT rates (16.7% versus 34.5%, P = 0.006), and
mortality rates (13.9% versus 26.7% P = 0.02) were lower
[12]. If prolonged blood storage is thrombophilic in
trauma, this could similarly increase DVT risk in critically
ill medical-surgical patients. In reconsidering PROTECT
and ABLE co-enrollment, we sought additional evidence.
Using an existing prospective observational study data-
base of 261 medical-surgical ICU patients screened for
DVT [13], we evaluated age of transfused blood as an
additional DVT risk factor. We also examined red blood
cell transfusion as a possible risk factor in this population
because in 349 trauma patients, transfusions increased
DVT risk [14]. We found that 126 (48.3%) patients had at
least one transfusion, and patients had a median of four
(interquartile range; IQR 2, 8) units. Multivariable ana-
lyses documented that neither red blood cell transfusion
nor storage age predicted DVT in medical-surgical
patients. Trends were counter to findings in trauma (for
example, red blood cells stored for ≤ 7 days had a higher
associated DVT risk compared to > 7 days (hazard ratio
5.3; 95% CI 1.3 TO 22.1)) [15]. Based on inconclusive
research evidence, the PROTECT and ABLE Steering
Committees affirmed co-enrollment into these trials.
Given the PROTECT sample size, we anticipated similar
transfusion rates and similar age of red blood cells trans-
fused in the two arms. The ABLE trial now includes
venous thromboembolism as a tertiary outcome.
Statistical analysis
We reported proportions with 95% confidence intervals
(CI), and mean and standard deviation (SD) or median
and IQR. We compared groups using Chi square, t-test
and Fisher’s Exact test. We examined univariate associa-
tions between co-enrollment rates (the dependent vari-
able) and other factors (independent variables) related to
characteristics of the patient, research coordinator, center
and trial. A P-value of < 0.01 was considered statistically
significant.
We conducted multivariable logistic regression analyses.
To avoid incorporation of highly correlated independent
variables into the model, we selected one of four measures
of research coordinator experience, one of three measures
of research infrastructure, and research consortium affilia-
tion rather than country. The following independent fac-
tors were analyzed: patient factors (age, sex, Acute
Physiology and Chronic Health Evaluation (APACHE) II
score, medical versus surgical status); individual consent-
ing (substitute decision-maker or patient); research coordi-
nator factors (years of experience obtaining consent for
studies in the ICU when PROTECT began); center factors
(number of ICU beds; number of full time research staff;
national research consortium affiliation (Canadian Critical
Care Trials Group or the Australian or New Zealand
Intensive Care Society Clinical Trials Group); and year
(pilot trial or year 1, 2, 3 and 4 of the full trial). Results are
summarized using odds ratios (OR) with 95% CI. A P-
value of < 0.01 was considered statistically significant.
We calculated the proportion of patients in each arm of
the PROTECT trial who were co-enrolled. To evaluate
whether co-enrollment affected patient safety, we re-
analyzed the proportion of patients in each arm who had
serious adverse events. To evaluate whether trial results
would be any different without co-enrolled patients, we
re-analyzed overall results excluding these patients.
Results
In 67 participating ICUs, 3,746 patients were enrolled in
PROTECT. Consent was declined for 810 patients.
Patients who were not enrolled in PROTECT due to
enrollment in another study represented 65 of 2,288
patients (2.8%) who were eligible but not randomized.
Those 65 patients were enrolled in 71 other studies, 41
(63.1%) of which were industry-funded.
Among the 3,746 patients in PROTECT, 713 (19.0%)
were co-enrolled in at least one other study (53.6% in a
randomized trial, 37.0% in an observational study and
9.4% in both types of studies). Co-enrollment rates
across participating centers ranged from 0 to 53.9% and
across participating countries from 1.1 to 26.0%. No co-
enrollment occurred in 30 of 67 (44.8%) centers.
Factors associated with co-enrollment in univariate ana-
lysis are presented in Table 1. Patients with higher illness
severity and medical conditions were more likely to be co-
enrolled than patients who were less ill and surgical.
Substitute decision-makers were more likely to agree to
co-enrollment than patients. Research coordinators with
more ICU experience, and those with more experience
obtaining consent in the ICU, were more likely to co-
enroll patients than those with less experience. Centers
with more ICU beds and centers affiliated with national
research consortia were more likely to co-enroll than
others. A higher proportion of patients were co-enrolled
in Canada, the United States and Australia than in Brazil,
Saudi Arabia and the United Kingdom. Co-enrollment
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was less common in the pilot phase of the trial than the
main trial.
In Table 2, we present the six factors independently
associated with co-enrollment in the multivariable analy-
sis. In order of decreasing strength of association, these
were: phase of the trial (all ORs > 8 for recruitment
beyond the pilot phase); center affiliation with a research
consortium (OR 5.59, 3.49 to 8.95); center size (all ORs >
10 for ICUs with > 15 beds); substitute decision-makers
providing consent rather than patients (OR 3.31, 2.03 to
5.41); experience of research coordinator (OR 2.67, 1.74
to 4.11 for > 10 years of experience compared to persons
whose first trial was PROTECT); and patient illness
severity (odds ratio (OR), 95%CI 1.35 (1.19 to 1.53 for
each 10-point increase in APACHE II score).
Table 3 summarizes characteristics of the studies into
which PROTECT patients were co-enrolled. The majority
were co-enrolled into another academic investigator-
initiated study (97.5%). Of 713 patients, 592 (83.0%) were
co-enrolled in one other study, 93 (13.0%) were co-
enrolled in two studies, and 28 (3.9%) were co-enrolled
in three or more studies.
Of 865 co-enrollments involving 713 patients, the most
common other international trials tested pharmaconutri-
tion, intensive glucose control, sedation interruption and
high frequency oscillation (Table 1). Observational stu-
dies were both quantitative (for example, registries,
audits, quality improvement studies, diagnostics, transla-
tional biology or long-term follow-up studies), and quali-
tative (for example, interviews, focus groups).
The proportion of patients co-enrolled in any study
was similar between the dalteparin group and the unfrac-
tionated heparin group (352 (18.8%) versus 361 (19.3%),
P = 0.74). There were no differences between groups in
Questions and co-enrollment  
reporting to   
Methods Centers 
 START: Discuss potential study for  
co-enrollment with respective PIs  
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Consider local REB guideline 
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Figure 2 Co-enrollment schema. In this figure, we outline steps taken to consider co-enrollment of one patient into one or more additional
studies. ABLE Trial, Age of Blood Evaluation Trial; ANZICS, Australian and New Zealand Intensive Care Society Clinical Trials Group; CCCTG,
Canadian Critical Care Trials Group; Fonda, fondaparinux; REB, Research Ethics Board; UFH, unfractionated heparin.
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patients enrolled in any randomized trial (209 (11.2%)
versus 239 (12.8%), P = 0.14), or the proportion in each
group enrolled in any of the five most common co-
enrollment studies (197 (10.5%) versus 223 (11.9%),
P = 0.20). Twenty PROTECT patients were co-enrolled
in ABLE (9 of 1,873 (0.5%) in the dalteparin group and
11 of 1,873 (0.6%) in the unfractionated heparin group),
P = 0.82.












Age, mean (SD) 61.4 (16.5) 61.4 (16.6) 61.4 (15.9) 0.996
Female, N (%)* 1,614 (43.3) 1,319 (43.8) 295 (41.4) 0.257
APACHE II score, mean (SD)** 21.5 (7.8) 21.1 (7.8) 23.3 (7.6) < 0.001
Medical admission type, N (%) 2,831 (75.6) 2,262 (74.6) 569 (79.8) 0.004
Person consenting, N (%)***
Patient 354 (9.5) 335 (11.1) 19 (2.7) < 0.001
Substitute decision-maker 3,380 (90.5) 2,686 (88.9) 694 (97.3)
Research coordinator characteristics
Years of non-research ICU experience, N (%)
0 years 572 (15.3) 491 (16.2) 81 (11.4) 0.003
> 0 to 10 years 1,254 (33.5) 1,017 (33.5) 237 (33.2)
> 10 years 1,920 (51.3) 1,525 (50.3) 395 (55.4)
Years of procuring consent for clinical studies in ICU, N (%)
0 years 302 (8.1) 268 (8.8) 34 (4.8) < 0.001
> 0 to 10 years 2,652 (70.8) 2,276 (75.0) 376 (52.7)
> 10 years 792 (21.1) 489 (16.1) 303 (42.5)
Center characteristics
Number of ICU beds screened, N (%)
< 15 beds 420 (11.2) 414 (13.6) 6 (0.8) < 0.001
15 to 20 beds 1622 (43.3) 1,218 (40.2) 404 (56.7)
> 20 beds 1,704 (45.5) 1,401 (46.2) 303 (42.5)
Full time ICU research staff, N (%)
< 1 FTE 286 (7.6) 280 (9.2) 6 (0.8) < 0.001
1 FTE 740 (19.8) 622 (20.5) 118 (16.5)
> 1 FTE 2,720 (72.6) 2,131 (70.3) 589 (82.6)
Formal trials group affiliation, N (%)
Yes 3,224 (86.1) 2,533 (83.5) 691 (96.9) < 0.001
No 522 (13.9) 500 (16.5) 22 (3.1)
Country, N (%)
Canada 2,456 (65.6) 1,818 (59.9) 638 (89.5) < 0.001
Australia 768 (20.5) 715 (23.6) 53 (7.4)
Brazil 275 (7.3) 272 (9.0) 3 (0.4)
Saudi Arabia 138 (3.7) 135 (4.5) 3 (0.4)
United States 91 (2.4) 77 (2.5) 14 (2.0)
United Kingdom 18 (0.5) 16 (0.5) 2 (0.3)
Characteristic of enrollment phase, N (%)
Pilot trial 128 (3.4) 126 (4.2) 2 (0.3) < 0.001
Year 1 556 (14.8) 504 (16.6) 52 (7.3)
Year 2 826 (22.1) 626 (20.6) 200 (28.1)
Year 3 1,009 (26.9) 761 (25.1) 248 (34.8)
Year 4 1,227 (32.8) 1,016 (33.5) 211 (29.6)
In this table, we compare patients, person consenting, approaches to consent and research environment associated with co-enrollment versus no co-enrollment.
Formal trials group affiliation refers to a center associated with either the Canadian Critical Care Trials Group or the Australian and New Zealand Intensive Care
Society Clinical Trials Group. P-values refer to results of univariate analyses. APACHE II score, Acute Physiology and Chronic Health Evaluation II score; ICU,
intensive care unit; SD, standard deviation.
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Among patients co-enrolled in other randomized
trials, rates of serious adverse events were similar
between the dalteparin (2 of 209, 1.0%) and unfractio-
nated heparin (0 of 239, 0.0%) groups, P = 0.14, as per
the main trial findings (7 of 1,873, 0.4%) versus 6 of
1,873, 0.3%), respectively, P = 0.74. Protocol violations
were also similar (data not shown). In Table 4, we show
that the overall PROTECT results excluding patients co-
enrolled in other randomized trials, which were no dif-
ferent than the results of all patients randomized [9].
That is, pulmonary embolism rates were lower in
patients receiving dalteparin compared to those receiv-
ing unfractionated heparin; rates of DVT, venous throm-
bosis and major bleeding were similar. No patients were
withdrawn or lost to follow-up whether co-enrolled or
not.
Discussion
In this international heparin thromboprophylaxis trial,
one-fifth of patients were co-enrolled in at least one
other study. Half of the co-enrollments were in rando-
mized trials, although a variety of study designs were
involved. Co-enrollment was limited to one or two
additional studies in 83% and 13% of patients, respec-
tively. These findings are consistent with membership
surveys of research consortia indicating that two was
the median number of randomized trials into which one
patient was enrolled [5].
Multivariate analysis showed that consent encounters
with substitute decision-makers were more likely to
involve co-enrollment than those with patients. This sug-
gests that more seriously ill patients are frequently eligi-
ble for several studies, yet too sick to make decisions
themselves, congruent with the finding that patients who
were co-enrolled were more seriously ill than those who
were not. Substitute decision-makers may seek several
research opportunities while helping to advance science,
so-called conditional altruism [16].
Research coordinators with greater consent experience
were more likely to co-enroll than others, suggesting that
professional maturity may foster sound judgment about
approaching persons for co-enrollment, whether training
enhances comfort and success with co-enrollment is
unclear. Co-enrollment occurred more often in larger
ICUs, and in centers affiliated with a national consor-
tium, perhaps reflecting group norms. More frequent





Age (10-year increase) 0.96 (0.91, 1.02) 0.155
Female 0.92 (0.77, 1.11) 0.403
APACHE II score (10-point increase) 1.35 (1.19, 1.53) < 0.001
Medical versus surgical 1.26 (1.01, 1.57) 0.041
Individual consenting
Substitute decision-maker versus patient 3.31 (2.03, 5.41) < 0.001
Years of procuring consent for clinical studies in ICU
> 0 to 10 years versus 0 years 0.83 (0.55, 1.25) < 0.001
> 10 years versus 0 years 2.67 (1.74, 4.11)
Center size (beds screened for PROTECT patients)
15 to 20 beds versus < 15 beds 20.06 (7.56, 53.25) < 0.001
> 20 beds versus < 15 beds 13.76 (5.15, 36.80)
Full time ICU research staff
1 FTE versus < 1 FTE 1.13 (0.41, 3.11) 0.966
> 1 versus < 1 FTE 1.10 (0.40, 3.03)
Formal trials group affiliation
Yes versus no 5.59 (3.49, 8.95) < 0.001
Year of PROTECT
Year 1 versus Pilot 8.22 (1.95, 34.61) < 0.001
Year 2 versus Pilot 32.89 (7.95, 135.98)
Year 3 versus Pilot 38.15 (9.24, 157.51)
Year 4 versus Pilot 24.53 (5.94, 101.25)
In this table, we present the independent factors associated with co-enrollment of one patient into two or more studies identified by multivariate regression
analysis, presented using odds ratios (OR) and 95% confidence intervals (95% CI). P-values refer to results of multivariate analyses. ANZICS, Australian and New
Zealand Intensive Care Society Clinical Trials Group; APACHE II score, Acute Physiology and Chronic Health Evaluation II score; CCCTG, Canadian Critical Care
Trials Group; FTE, full time equivalent; ICU, intensive care unit.
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during the full trial than the pilot phase, facility with co-
enrollment may have increased over time.
Participation in another study was the reason why 65 eli-
gible patients were not enrolled in PROTECT; 63% of
these studies were industry-initiated. Only 2% of PRO-
TECT patients were co-enrolled in industry studies. Gen-
erally, industry-funded trials, compared to other trials, are
more likely to exclude individuals due to age, comorbid-
ities and concomitant medications, raising concerns about
their generalizability [17]. However, if industry trials prohi-
bit co-enrollment in academic studies, selection bias in
academic trials may result, as well as slower completion,
thereby delaying answers to publicly motivated research
questions. Certainly, co-enrollment in trials of investiga-
tional drugs or devices is imprudent due to difficulty mon-
itoring safety and interpreting harm. Since patients in the
investigator-informed, industry-funded trial comparing
drotrecogin alfa to placebo in patients with persistent sep-
tic shock (PROWESS-SHOCK, NCT00604214) [18] would
typically receive heparin thromboprophylaxis in the
absence of contraindications, PROTECT co-enrollment
was permitted. We identified three patients who were eli-
gible for PROTECT but not recruited because of enroll-
ment in PROWESS-SHOCK, and no PROTECT patients
who were co-enrolled in PROWESS-SHOCK.
One major focus regarding permissible co-enrollment in
two academic trials is the biologic plausibility of the two
interventions having a potentiating or attenuating effect
on each other. Having identical primary outcomes in two
academic trials would not be a sole criterion for prohibit-
ing co-enrollment, especially when treatment effects are
expected to be modest, which is common in critical care.
For example, if two trials had the same primary outcome
of mortality (for example, a trial comparing starch resusci-
tation vs normal saline in septic shock and intensive insu-
lin therapy vs liberal glucose management in heterogenous
ICU patients), the two interventions would likely be con-
sidered unrelated, and co-enrollment would be permitted,
because starch and antioxidants would not be known to
mediate their effect on mortality through related mechan-
isms. Several additional scientific issues need careful
Table 3 Co-enrollment study characteristics.
N (% of 713 patients)
Type of other study
Randomized trial 380 (53.3)
Observational study 265 (37.2)
Both 68 (9.5)













In this table, among the 713 patients who were co-enrolled in another study,
we present the co-enrollment study type (randomized trial, observational
study), study genesis (investigator-initiated versus industry-initiated), affiliation
with a research consortia, and the number of studies into which PROTECT
patients were co-enrolled. The bottom half of the table outlines, of the 865
co-enrollments, which studies were involved. ANZICS, Australian and New
Zealand Intensive Care Society Clinical Trials Group; CCCTG, Canadian Critical
Care Trials Group.



















Primary outcome: proximal leg deep vein
thrombosis
94 (5.1) 108 (5.9) 0.91 (0.68,
1.23)
83 (5.0) 93 (5.7) 0.87 (0.63,
1.21)
Any pulmonary embolism 22 (1.2) 42 (2.3) 0.48 (0.27,
0.84)
19 (1.1) 35 (2.1) 0.48 (0.26,
0.89)
Any venous thromboembolism 150 (8.2) 184 (10.0) 0.87 (0.69,
1.10)
133 (8.0) 161 (9.9) 0.83 (0.64,
1.07)
Major bleeding 100 (5.5) 105 (5.7) 0.98 (0.73,
1.31)
88 (5.3) 93 (5.7) 0.94 (0.69,
1.28)
Heparin-induced thrombocytopenia 5 (0.3) 12 (0.7) 0.47 (0.16,
1.37)
5 (0.3) 10 (0.6) 0.56 (0.18,
1.67)
Hospital mortality 395 (21.7) 444 (24.3) 0.91 (0.79,
1.05)
372 (22.4) 391 (23.9) 0.95 (0.82,
1.10)
In this table we report the main results of the original trial including all patients, and results including only those patients, (209 in the dalteparin group and 239
in the unfractionated heparin group), who were not co-enrolled in another randomized trial (1,664 in the dalteparin arm and 1,633 in the unfractionated heparin
arm). CI, confidence interval; RCT, randomized clinical trial; UFH, unfractionated heparin.
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consideration regarding co-enrollment, such as projected
impact on statistical power, outcome ascertainment bias,
increased risk of adverse events and the ultimate interpre-
tation of study results. We recommend widespread
consultation about the merits and demerits of various co-
enrollment pairs before and during conduct of a trial.
Furthermore, specific approaches to data collection and
analysis can be established a priori if concerns exist about
co-enrollment. Shared definitions and case report forms
for use across studies could help [3], as we used for PRO-
TECT and ABLE. New research influencing previous co-
enrollment decisions should prompt revisiting previous
decisions as studies unfold. Documenting consecutive and
concurrent co-enrollment eligibility and consent rates
throughout a trial, and transparent reporting of co-enroll-
ment upon completion, including effect modification and
risk of harm, will help to disseminate co-enrollment pat-
terns, and provide data to examine its actual rather than
perceived impact. If concerns exist and trialists are willing
to exchange randomization codes, unadjusted and adjusted
analyses can be conducted to evaluate the impact not just
of substantial co-enrollment of patients in one trial on the
results of the other trial, and vice versa, but also the impact
of each specific allocation arm.
Although an understanding of all available treatment
options is important for informed consent for medical
therapy, there is no similar perception that patients should
be informed of all available studies for which they are eligi-
ble. Indeed, most human subjects research discourse deals
with protection from harm rather than opportunity for
participation [1], which is particularly germane to co-
enrollment. More open discussion will help to elucidate
key ethical issues, since the vulnerability of critically ill
patients [19] raises concern about adverse effects from co-
enrollment. We found that PROTECT patients co-
enrolled in randomized trials were not more likely to have
serious adverse events or protocol violations compared to
patients who were not co-enrolled. Post hoc analyses of
PROTECT omitting patients co-enrolled in randomized
trials yielded the same overall results as the main analysis.
Finally, no PROTECT patients were lost to follow-up,
thus, no co-enrolled patients were withdrawn.
In 2007, a tri-national survey showed that only 11% of
respondents indicated that their local Institutional
Review Board had a co-enrollment policy, whereas 35%
reported a local ICU guideline [5]. Co-enrollment guide-
lines exist for adult resuscitation studies [4], pediatric
[20] and adult [10] critical care. Public health mandates
to answer research questions quickly during pandemics
have encouraged co-enrollment of patients in treatment
and observational studies [21]. Professional position
statements about whether, when, why and how to co-
enroll will raise awareness and facilitate stakeholder
dialogue.
Limitations of this study include our inability to explore
the decisional burden on substitute decision-makers,
patients and research coordinators. However, in another
four-month single center study, we found consent rates
similar for any single enrollment (84%) and co-enrollment
(79%) opportunity [22]. We could not document rates or
reasons for no co-enrollment, or which person declined
(for example, patient, substitute decision-maker, physician,
surgeon, anesthesiologist). Examining the choice of which
study to pursue if a patient was eligible for more than one
was beyond the scope of this project. However, investiga-
tors report that when approaching persons for co-enroll-
ment in a randomized trial, they consider trial rigor and
relevance, potential for benefit or harm, consortium affilia-
tion and remuneration [5].
Strengths of this study include comprehensive docu-
mentation of co-enrollment throughout a multicenter
trial. Investigators used a prospective, transparent frame-
work for co-enrollment decisions, independently examin-
ing each pair of studies, guided by independent
Institutional Review Boards, and research consortia.
Using multivariate analysis, significant predictors of co-
enrollment were identified, adjusting for confounding.
We examined the impact on patient and trial outcomes.
Representation from diverse ICUs and countries
enhances the generalizability of these findings, which
may apply to other academic trials testing currently avail-
able interventions.
Conclusions
Co-enrollment was common in this thromboprophylaxis
trial, and was strongly associated with specific features of
the patients, research personnel, setting and study. Co-
enrollment was an effective, feasible method to enhance
recruitment, provided that the patients or substitute deci-
sion-maker, clinicians, principal investigators, steering
committees, research consortium and local Institutional
Review Boards agreed. Co-enrollment did not influence
overall trial results, patient safety or adverse events.
Further scientific debate, ethical analysis and research are
needed on the complex topic of co-enrollment for criti-
cally ill patients.
Key messages
• In this international heparin thromboprophylaxis
trial of 3,746 patients, one-fifth of patients were co-
enrolled in at least one other study. Half of the co-
enrollments were in randomized trials, although a
variety of study designs were involved and almost all
co-enrollments were in academic investigator-
initiated studies.
• In decreasing strength of association, six factors
were independently associated with co-enrollment:
later phase of the trial compared to the pilot phase,
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center affiliation with a research consortium, larger
center size, substitute decision-makers providing con-
sent rather than patients, greater research coordinator
experience and higher patient illness severity.
• Co-enrollment did not influence overall trial results,
patient safety or adverse events.
• Before and during a trial, we suggest widespread con-
sultation among investigators, clinicians, trial steering
committees, research consortia and local Institutional
Review Boards about the scientific, psychosocial and
logistic effects of various co-enrollment pairs.
• Transparent reporting, scholarly discourse, ethical
analysis and further research are needed on the com-
plex topic of co-enrollment during critical illness.
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